

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status **Final**

Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE**XRAY-CHEST**

»» BOTH THE LUNG FIELDS ARE CLEAR
 »» BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR
 »» BOTH THE HILA ARE NORMAL
 »» CARDIAC AND AORTIC SHADOWS APPEAR NORMAL
 »» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL
 »» VISUALIZED BONY THORAX IS NORMAL
 IMPRESSION NORMAL

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT
 RELEVANT PAST HISTORY NOT SIGNIFICANT
 RELEVANT PERSONAL HISTORY MARRIED, 03 CHILD, VEG.
 MENSTRUAL HISTORY (FOR FEMALES) NOT SIGNIFICANT
 LMP (FOR FEMALES) 31/01/2024
 OBSTETRIC HISTORY (FOR FEMALES) P3A1L3, 1 FTNVD, 1 LSCS (TWINS)
 LCB (FOR FEMALES) 05 YRS.
 RELEVANT FAMILY HISTORY NOT SIGNIFICANT
 OCCUPATIONAL HISTORY HOME MAKER.
 HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.47 mts
 WEIGHT IN KGS. 59.90 Kgs



Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist

Page 1 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BMI	28	BMI & Weight Status as follows: Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese	kg/sqmts
-----	----	---	----------

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
CAROTID PULSATION	NORMAL
BREAST (FOR FEMALES)	NORMAL
TEMPERATURE	NORMAL
PULSE	82/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT
RESPIRATORY RATE	NORMAL

CARDIOVASCULAR SYSTEM

BP	102/71 MM HG (SITTING)	mm/Hg
PERICARDIUM	NORMAL	
APEX BEAT	NORMAL	
HEART SOUNDS	S1, S2 HEARD NORMALLY	

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL
 MOVEMENTS OF CHEST SYMMETRICAL
 BREATH SOUNDS INTENSITY NORMAL
 BREATH SOUNDS QUALITY VESICULAR (NORMAL)
 ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL
 VENOUS PROMINENCE ABSENT
 LIVER NOT PALPABLE
 SPLEEN NOT PALPABLE
 HERNIA ABSENT
 ANY OTHER COMMENTS NIL

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL
 CRANIAL NERVES NORMAL
 CEREBELLAR FUNCTIONS NORMAL
 SENSORY SYSTEM NORMAL
 MOTOR SYSTEM NORMAL
 REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

JOINTS

NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA

NORMAL

EYELIDS

NORMAL

EYE MOVEMENTS

NORMAL

CORNEA

NORMAL

DISTANT VISION RIGHT EYE WITHOUT
GLASSES

6/9

DISTANT VISION LEFT EYE WITHOUT
GLASSES

6/9

NEAR VISION RIGHT EYE WITHOUT GLASSES

N/6

NEAR VISION LEFT EYE WITHOUT GLASSES

N/6

COLOUR VISION

NORMAL

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL

NORMAL

TYMPANIC MEMBRANE

NORMAL

NOSE

NO ABNORMALITY DETECTED

SINUSES

NORMAL

THROAT

NORMAL

TONSILS

NOT ENLARGED

BASIC DENTAL EXAMINATION

TEETH

CARIES

GUMS

HEALTHY

ANY OTHER COMMENTS

STAINS/CALCULUS- ++/++.
ADV- ORAL PROPHYLAXIS, RESTORATION.



Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist

Page 4 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : **0062XB002627**

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--------------------	--------------	---------	-------------------------------	-------

SUMMARY

RELEVANT HISTORY

NOT SIGNIFICANT

RELEVANT GP EXAMINATION FINDINGS

NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS

LIPID PROFILE - ABOVE NORMAL LIMITS

RELEVANT NON PATHOLOGY DIAGNOSTICS

USG ABD - GB CALCULUS

REMARKS / RECOMMENDATIONS

CURTAIL FAT INTAKE; ORAL PROPHYLAXIS; SURG. SPL. CONSULTATION

FITNESS STATUS

FITNESS STATUS

FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)



Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist

Page 5 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHINEW DELHI 110030
8800465156ACCESSION NO : **0062XB002627**

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE**ULTRASOUND ABDOMEN****ULTRASOUND ABDOMEN**

Liver is normal in size, outline & normal echotexture. No obvious focal parenchymal lesion/biliary dilatation is seen. Hepatic veins and portal venous radicals are normal.

Gall bladder is partially distended and shows a calculus in the lumen of size 13.0mm.

Common bile duct is not dilated. Portal vein is normal in course and caliber.

Pancreas

Pancreas is normal in size, outline and echotexture. No evidence of any focal lesion or calcification is seen.

Pancreatic duct is not dilated.

Spleen

Spleen is normal in size, outline and echotexture. No focal lesion/ calcification is seen.

Kidneys

Both kidneys are normal in size, outline and echotexture. Corticomedullary differentiation is well maintained.

Parenchymal thickness is normal. No mass lesion, calculus or hydronephrosis is seen.

No significant retroperitoneal lymphadenopathy/ascites is seen.

Urinary Bladder

Urinary bladder is adequately distended with normal outline. No mass lesion, calculus or diverticulum is noted in the urinary bladder. Urinary bladder wall thickness is normal.

Uterus

Uterus is anteverted with normal in size outline and shows heterogenous echotexture with hazy endo-myometrial interface. Endometrial thickness is 10mm. No obvious myometrial/endometrial pathology seen.

No obvious adnexal pathology is seen. Adv- TVS for better evaluation.

POD is clear.

Correlate clinically

TMT OR ECHO**CLINICAL PROFILE**

NEGATIVE



Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist

Page 6 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

MEDICAL

HISTORY.*****
THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history; as well as the comprehensiveness of the diagnostic panel which has been requested for .These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

Basis the above, Agilus diagnostic classifies a candidate's Fitness Status into one of the following categories:

- Fit (As per requested panel of tests) – AGILUS Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.
- Fit (with medical advice) (As per requested panel of tests) - This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician's consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job.
- Fitness on Hold (Temporary Unfit) (As per requested panel of tests) - Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc.
- Unfit (As per requested panel of tests) - An unfit report by Agilus diagnostic Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138376		ACCESSION NO : 0062XB002627	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156		AGE/SEX : 38 Years Female DRAWN : CLIENT PATIENT ID: RECEIVED : 24/02/2024 07:58:48 ABHA NO : REPORTED : 26/02/2024 15:20:31	

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	12.7	12.0 - 15.0	g/dL
METHOD : CYANMETHEMOGLOBIN METHOD			
RED BLOOD CELL (RBC) COUNT	4.62	3.8 - 4.8	mil/ μ L
METHOD : IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	8.65	4.0 - 10.0	thou/ μ L
METHOD : IMPEDANCE			
PLATELET COUNT	328	150 - 410	thou/ μ L
METHOD : IMPEDANCE			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	39.9	36 - 46	%
METHOD : CALCULATED			
MEAN CORPUSCULAR VOLUME (MCV)	86.3	83 - 101	fL
METHOD : CELL COUNTER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.5	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.9	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	13.9	11.6 - 14.0	%
METHOD : CALCULATED			
MENTZER INDEX	18.7		
METHOD : CALCULATED PARAMETER			
MEAN PLATELET VOLUME (MPV)	11.9 High	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

WBC DIFFERENTIAL COUNT

NEUTROPHILS	60	40 - 80	%
METHOD : IMPEDANCE / MICROSCOPY			
LYMPHOCYTES	32	20 - 40	%
METHOD : IMPEDANCE / MICROSCOPY			

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
MONOCYTES		5	2 - 10	%
METHOD : IMPEDANCE / MICROSCOPY				
EOSINOPHILS		2	1 - 6	%
METHOD : IMPEDANCE / MICROSCOPY				
BASOPHILS		1	0 - 2	%
METHOD : MICROSCOPIC EXAMINATION				
ABSOLUTE NEUTROPHIL COUNT		5.19	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		2.77	1 - 3	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.43	0.20 - 1.00	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.17	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0.09	0.02 - 0.10	thou/ μ L
METHOD : CALCULATED PARAMETER				
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.9		
METHOD : CALCULATED PARAMETER				

Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD

E.S.R	02	0 - 20	mm at 1 hr
-------	----	--------	------------

METHOD : WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	5.5	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
-------	-----	--	---

METHOD : HPLC

ESTIMATED AVERAGE GLUCOSE(EAG)	111.2	< 116.0	mg/dL
--------------------------------	-------	---------	-------

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm /hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:



Dr. Arvind Semalti, MBBS, MD
Pathology
Consultant Pathologist

Page 10 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160, Pocket D-11 Sector 8, Rohini

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138376		ACCESSION NO : 0062XB002627	AGE/SEX : 38 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156		PATIENT ID : VARSF30088562	DRAWN :
		CLIENT PATIENT ID:	RECEIVED : 24/02/2024 07:58:48
		ABHA NO :	REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods,falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in

- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ACCESSION NO : **0062XB002627**

AGE/SEX : 38 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI

PATIENT ID : VARSF30088562

DRAWN :

NEW DELHI 110030
8800465156

CLIENT PATIENT ID:

RECEIVED : 24/02/2024 07:58:48

ABHA NO :

REPORTED : 26/02/2024 15:20:31

Test Report Status **Final**

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD**

ABO GROUP

TYPE O

METHOD : TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.



Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist

Page 12 Of 25



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING,FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	108 High	Normal <100 Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021)	mg/dL
---------------------------	-----------------	--	-------

METHOD : HEXOKINASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)	120	70 - 140	mg/dL
---------------------------------	-----	----------	-------

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL	202 High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
--------------------	-----------------	--	-------

METHOD : CHOLESTEROL OXIDASE, ESTERASE,PEROXIDASE

TRIGLYCERIDES	107	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
---------------	-----	---	-------

METHOD : ENZYMATIC, END POINT

HDL CHOLESTEROL	44	< 40 Low >/=60 High	mg/dL
-----------------	----	------------------------	-------

METHOD : DIRECT MEASURE POLYMER-POLYANION

CHOLESTEROL LDL	137 High	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
-----------------	-----------------	--	-------

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
NON HDL CHOLESTEROL		158 High	Desirable-Less than 130 Above Desirable-130-159 Borderline High-160-189 High-190-219 Very High- >or =220	mg/dL
METHOD : CALCULATED				
VERY LOW DENSITY LIPOPROTEIN		21.4		mg/dL
CHOL/HDL RATIO		4.6 High	3.3 - 4.4: Low Risk 4.5 - 7.0: Average Risk 7.1 - 11.0: Moderate Risk >11.0: High Risk	
LDL/HDL RATIO		3.1 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status **Final** **Results** **Biological Reference Interval** **Units**

Extreme Risk Group Category A	<50 (Optional goal <OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80
Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.41	Upto 1.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE)			
BILIRUBIN, DIRECT	0.11	Upto 0.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE)			
BILIRUBIN, INDIRECT	0.30	0.00 - 0.90	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.2	6.4 - 8.3	g/dL
ALBUMIN	4.2	3.97 - 4.94	g/dL
METHOD : BROMOCRESOL PURPLE			
GLOBULIN	3.0	2.0 - 4.0	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.4	1.0 - 2.0	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	17	0 - 32	U/L
METHOD : IFCC WITH PYRIDOXAL 5 PHOSPHATE			
ALANINE AMINOTRANSFERASE (ALT/SGPT)	17	0 - 33	U/L
METHOD : UV WITH P5P-IFCC			
ALKALINE PHOSPHATASE	96	35 - 104	U/L
METHOD : PNPP, AMP BUFFER-IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	43 High	5 - 36	U/L
METHOD : G-GLUTAMYL-CARBOXY-NITROANILIDE-IFCC			
LACTATE DEHYDROGENASE	135	135 - 214	U/L
METHOD : L TO P, IFCC			

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN	15	6 - 20	mg/dL
METHOD : UREASE - UV			

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CREATININE, SERUM

CREATININE METHOD : ALKALINE PICRATE	0.83	0.5 - 0.9	mg/dL
---	------	-----------	-------

BUN/CREAT RATIO

BUN/CREAT RATIO	18.07 High	5.00 - 15.00	
-----------------	-------------------	--------------	--

URIC ACID, SERUM

URIC ACID METHOD : URICASE, COLORIMETRIC	4.0	2.4 - 5.7	mg/dL
---	-----	-----------	-------

TOTAL PROTEIN, SERUM

TOTAL PROTEIN METHOD : BIURET	7.2	6.4 - 8.3	g/dL
----------------------------------	-----	-----------	------

ALBUMIN, SERUM

ALBUMIN METHOD : BROMOCRESOL PURPLE (BCP) DYE-BINDING	4.2	3.97 - 4.94	g/dL
--	-----	-------------	------

GLOBULIN

GLOBULIN METHOD : CALCULATED PARAMETER	3.0	2.0 - 4.0	g/dL
---	-----	-----------	------

ELECTROLYTES (NA/K/CL), SERUM

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ACCESSION NO : 0062XB002627

AGE/SEX : 38 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI

PATIENT ID : VARSF30088562

DRAWN :

NEW DELHI 110030
8800465156

CLIENT PATIENT ID:

RECEIVED : 24/02/2024 07:58:48

ABHA NO :

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
SODIUM, SERUM		138	136 - 145	mmol/L
METHOD : ISE INDIRECT				
POTASSIUM, SERUM		4.86	3.3 - 5.1	mmol/L
METHOD : ISE DIRECT				
CHLORIDE, SERUM		104	98 - 106	mmol/L
METHOD : ISE INDIRECT				

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants [SSRI], antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO ₃ ⁻), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). **Drugs:** corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), **Drugs:** insulin, ethanol, propranolol; sulfonyleureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

Dr. Arvind Semalti, MBBS, MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160, Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ACCESSION NO : 0062XB002627

AGE/SEX : 38 Years Female

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI

PATIENT ID : VARSF30088562

DRAWN :

NEW DELHI 110030
8800465156

CLIENT PATIENT ID:

RECEIVED : 24/02/2024 07:58:48

ABHA NO :

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM- Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM- Higher than normal level may be due to:

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM- Causes of Increased levels: Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome **Causes of decreased levels:** Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM- is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM- Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Arvind Semalti, MBBS, MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160, Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138376		ACCESSION NO : 0062XB002627	AGE/SEX : 38 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156		PATIENT ID : VARSF30088562	DRAWN :
		CLIENT PATIENT ID:	RECEIVED : 24/02/2024 07:58:48
		ABHA NO :	REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW
APPEARANCE	CLEAR

CHEMICAL EXAMINATION, URINE

PH	5.0	4.5 - 7.5
SPECIFIC GRAVITY	1.015	1.005 - 1.030
PROTEIN	NOT DETECTED	NEGATIVE
GLUCOSE	NOT DETECTED	NEGATIVE
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NEGATIVE
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	0-1	0-5	/HPF
EPITHELIAL CELLS	1-2	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	

REMARKS NOTE:- MICROSCOPIC EXAMINATION OF URINE IS PERFORMED BY CENTRIFUGE URINARY SEDIMENT.



Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD

PAP stain

Specimen Type : Conventional PAP smear

Received two unstained slides fixed in alcohol.

Reporting system:- 2014 The Bethesda system of reporting cervical cytology.

Specimen Adequacy - Satisfactory for evaluation

Microscopy :

Smears examined show superficial and intermediate squamous epithelial cells.

Endocervical cells not seen

Transformation zone not seen.

Background shows moderate inflammation.

Flora is normal.

No atypia/ fungus/ parasites seen.

Interpretation : Negative for intraepithelial lesion or malignancy (NILM).

Comment :

Pap smear cytology is a screening procedure.

Corroboration of cytopathologic findings with colposcopic /local examination and ancillary findings is recommended.

Test was done by manual method.



Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138376 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0062XB002627	AGE/SEX : 38 Years	Female
	PATIENT ID : VARSF30088562	DRAWN :	
	CLIENT PATIENT ID :	RECEIVED : 24/02/2024 07:58:48	
	ABHA NO :	REPORTED : 26/02/2024 15:20:31	

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION,STOOL

COLOUR SAMPLE NOT RECEIVED

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3	139.40	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	ng/dL
T4	7.57	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	µg/dL
TSH (ULTRASENSITIVE)	3.360	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000	µIU/mL

Interpretation(s)

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level

is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
---------	-----	----------	-----	----------	---------------------

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0062XB002627

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini



Patient Ref. No. 77500006548245

PATIENT NAME : VARSHA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138376

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : **0062XB002627**

PATIENT ID : VARSF30088562

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 38 Years Female

DRAWN :

RECEIVED : 24/02/2024 07:58:48

REPORTED : 26/02/2024 15:20:31

Test Report Status **Final**

Results

Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062

Page 25 Of 25


Dr. Arvind Semalti, MBBS,MD
Pathology
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
Plot No.160,Pocket D-11 Sector 8, Rohini

New Delhi, 110085
New Delhi, India
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 77500006548245